Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Income from Continuing Operations (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Income from Continuing Operations for 7 consecutive years, with 21749000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 56.27% to 21749000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 147516000.0, a 29.86% increase, with the full-year FY2025 number at 147516000.0, up 29.86% from a year prior.
  • Income from Continuing Operations was 21749000.0 for Q4 2025 at Pliant Therapeutics, up from 26301000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 21749000.0 in Q4 2025 to a low of 57763000.0 in Q3 2024.
  • A 5-year average of 36971950.0 and a median of 36067000.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: tumbled 307.24% in 2021, then skyrocketed 56.27% in 2025.
  • Pliant Therapeutics' Income from Continuing Operations stood at 24531000.0 in 2021, then plummeted by 40.99% to 34586000.0 in 2022, then decreased by 18.86% to 41109000.0 in 2023, then fell by 20.98% to 49732000.0 in 2024, then surged by 56.27% to 21749000.0 in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Income from Continuing Operations are 21749000.0 (Q4 2025), 26301000.0 (Q3 2025), and 43300000.0 (Q2 2025).